

wherein

A represents an angiotensin peptide moiety;

X represents an amino acid;

Y represents an amino acid having a side chain with a free -SH, -OH or -COOH group;

L represents an organic linker capable of binding a group ((A)-X<sub>n</sub>) - at one or more sites,

e.g. capable of binding up to 10 (A)X<sub>n</sub> moieties;

n and r are each = 0-20;

m and s are each  $\geq 1$ , e.g. 1 to 10, preferably 1, 2, 3 or 4; and

p, q and t are each 0 or 1;

wherein X may be attached at the N- or C-terminus of the angiotension peptide moiety  
with the proviso that if  $m \geq 2$ , then  $p=1$ , or if  $s \geq 2$ , then  $q=1$ .

7. (Amended) The use as claimed in [any one of claims 5 or 6] claim 5 wherein L is a peptide chain.

8. (Amended) The use as claimed in [any one of claims 5 to 7] claim 5 wherein n and r are each 0-10.

9. (Amended) The use as claimed in [any one of claim 5 to 8] claim 5 wherein m and s are each  $< 8$ .

10. (Amended) The use as claimed in [any one of claims 5 to 9] claim 5 wherein X is an amino acid having no side chain or a hydrocarbyl side chain (preferably an alkyl, C<sub>3-7</sub> cycloalkyl or cycloalkenyl, C<sub>3-7</sub> cycloalkyl- or cycloalkenyl-alkyl, alkaryl, aralkyl or alkarylalkyl moiety in which each alkyl moiety may be saturated or unsaturated and contains up to 6 carbons and each aryl moiety is preferably a phenyl ring), particularly preferably an aliphatic side chain.

11. (Amended) The use as claimed in [any one of claims 5 to 10] claim 5 wherein X

is glycine, alanine,  $\beta$ -alanine, valine, leucine or isoleucine.

12. (Amended) The use as claimed in [any one of claims 5 to 11] claim 5 wherein the angiotensin derivative is selected from

(A)-X<sub>n</sub>-Y (II)

(A)-X<sub>n</sub>-L-Y (III)

((A)-X<sub>n</sub>)<sub>m</sub>-L-Y (IV)

(A)-X<sub>n</sub>-L-Y-L-X<sub>r</sub>-(A) (V)

wherein A, X, L, n and r are as hereinbefore defined and  $m \geq 2$ .

13. (Amended) The use as claimed in [any one of the preceding claims] claim 1 wherein the angiotensin derivative is selected from

(A)-Gly Cys

(A)-Cys

(A)-Tyr

N-acetyl-Cys-(A)

Tyr - (A)

N-acetyl-Cys-Gly-(A)

Cys - (A)

(A) - N-acetyl-Cys

where A is angiotensin I or II.

14. (Amended) The use as claimed in [any one of the preceding claims] claim 1 wherein the angiotensin derivative elicits a cross-reactive immune response with angiotensin I,

angiotensin II, and/or angiotensinogen molecules.

A2  
CONT.  
15. (Amended) The use as claimed in [any one of the preceding claims] Claim 1 wherein the angiotensin derivative is conjugated to a carrier.

A3  
18. (Amended) The use as claimed in [any one of the preceding claims] claim 1 wherein said disease is congestive heart failure or hypertension.

A4  
20. (Amended) A pharmaceutical composition comprising an angiotensin derivative as defined in claim 5 [any one of claims 1-14, or a conjugated angiotensin derivative as defined in any of claims 15 to 17,] together with one or more pharmaceutically acceptable carriers or excipients.

21. (Amended) An angiotensin derivative as defined in [any one of claims 1-17] claim 5 for use in therapy.

A5  
23. (Amended) An angiotensin derivative as claimed in [any one of] claim 22 wherein L is a peptide chain.

24. (Amended) An angiotensin derivative as claimed in [any one of claims 22 or 23] claim 22 wherein n and r are each 0-10.

25. (Amended) An angiotensin derivative as claimed in [any one of claims 22 to 24] claim 22 wherein m and s are each  $\leq 8$ .

26. (Amended) An angiotensin derivative as claimed in [any one of claims 22 to 25] claim 22 wherein X is an amino acid having no side chain or a hydrocarbyl side chain (preferably an alkyl, C<sub>3-7</sub> cycloalkyl or cycloalkenyl, C<sub>3-7</sub> cycloalkyl-or cycloalkenyl-alkyl, alkaryl, aralkyl or alkarylalkyl moiety in which each alkyl moiety may be saturated or unsaturated and contains up to

6 carbons and each aryl moiety is preferably a phenyl ring), particularly preferably an aliphatic side chain.

27. (Amended) An angiotensin as claimed in [any one of claims 22 to 26] claim 22 wherein X is glycine and alanine,  $\beta$ -alanine, valine, leucine or isoleucine.

28. (Amended) An angiotensin derivative as claimed in [any one of claims 22 to 27] claim 22 selected from

(A)-X<sub>n</sub>-Y (II)

(A)-X<sub>n</sub>-L-Y (III)

((A)-X<sub>n</sub>)<sub>m</sub>-L-Y (IV)

(A)-X<sub>n</sub>-L-Y-L-S<sub>r</sub>-(A) (V)

wherein A, X, L, n and r are as hereinbefore defined and  $m \geq 2$ .

29. (Amended) An angiotensin derivative as claimed in [any one of claims 22 to 28] claim 22 selected from

N-acetyl-Cys-(A)

Tyr-(A)

N-acetyl-Cys-Gly-(A)

Cys-(A)

where A is angiotensin I.

30. (Amended) An angiotensin derivative as claimed in [any one of claims 22 to 29] claim 22 which elicits a cross-reactive immune response with angiotensin I, angiotensin II, and/or angiotensinogen molecules.

A5  
CONT.

31. (Amended) An angiotensin derivative as claimed in [any one of claims 22 to 30]  
claim 22 conjugated to a carrier.

---

A6

34. (Amended) A method of combatting conditions associated with activation of  
the renin-angiotensin system comprising administering an angiotensin derivative as defined in [any  
one of claims 1-17] claim 5.

---

35. (Amended) A nucleic acid molecule coding for a linear angiotensin peptide  
derivative as claimed in [any one of claims 1-17] claim 5 and nucleic acid molecules with  
sequences complementary thereto.

---

A7

38. (Amended) A method of combatting conditions associated with activation of  
the renin-angiotensin system comprising administering a nucleic acid molecule coding for a linear  
angiotensin peptide derivative as claimed in [any one of claims 1-16] claim 1 or an expression  
vector comprising a nucleic acid molecule coding for an angiotensin peptide derivative.

---

#### REMARKS

The foregoing amendments to the claims are made solely to remove multiple  
dependencies. No new matter has been added.

It is not believed that extensions of time or fees for net addition of claims are required,  
beyond those that may otherwise be provided for in documents accompanying this paper.